Daily Top 50 Gainers & Losers

Market Regime — the colored bar under each day is the market's overall “weather,” scored from the indexes (trend, fear/VIX, small-cap breadth). It's market-wide context, not a stock pick: even a great company gets dragged down in a red tape. Read it to gauge when to lean in vs. wait for calmer water — click any day for the full read.

Risk-On · supportive Neutral Risk-Off · headwind Stress · fear

Market Recap · Monday, May 18, 2026

Snapshot: May 18, 2026 · 6:00 PM 100 stocks analyzed

Flat Day

Mon, May 18, 2026 Divergent High

High dispersion chaos as small caps and tech collide—Russell down 0.65%, NASDAQ down 0.51%, yet 50 stocks soared averaging 40% while 50 tanked averaging -26%, with micro-cap rig…

55% Extreme single-stock dispersion overwhelmed the flat index picture: 50 gainers averaged +40.4% (AMPGR +350%, GOVX +79.7% on Ebola vaccine funding, HIVE +28.6% on $3.5B AI data center), while 50 losers averaged -25.9%, with BTM cratering -73.2% on Chapter 11 bankruptcy and GOSS sliding -43% on wider losses. Technology captured 45% of gainers but still led losers (21%), signaling brutal sector infighting rather than broad movement.
30% Russell 2000 and NASDAQ both negative on the day (–0.65% and –0.51%) while S&P barely budged (–0.07%), marking a rare divergent regime where small-cap and tech weakness coexisted despite a handful of AI/infrastructure winners. VIX calmed 3.3%, confirming no panic underpinned the moves—instead surgical selling of specific names and a 4-day WOK streak plus 3-day LABT streak in losers showed persistent weakness in micro-cap and biotech.
15% Five debutant gainers (GOVX, NXXT, SACH, TOP, HIVE) resurfaced alongside news-grounded winners like RAMP (+27.3% on Publicis $2.2B acquisition), TTRX (+21% on ex-FDA chief hire), and BRC (+18.9% on earnings beat), while equally strong news like LABT's positive DFU trial data and DSGN's Friedreich data failed to stick (both down sharply), underscoring a market that rewarded M&A, financing, and execution while punishing clinical announcements in a risk-off micro-cap tone.

Technology drove 45% of gainers 5 names returned after long absences WOK · 4-day losers streak LABT · 3-day losers streak GOVX — first appearance NXXT — first appearance

Market Regime

Mon, May 18, 2026 Neutral conf: high macro · prototype

+13

Neutral −100 … +100 · + tailwind / − headwind

VIX17.8 p59 Drawdown-1.3% Held2d · nascent SinceMay 15

Top drivers: S&P vs 50d avg ▲ Small-cap leadership ▼ S&P 20d return ▲

processId: history-market-regime

Market Indexes

Mon, May 18, 2026 4

S&P 500

7,403.10

−5.40

-0.07%

NASDAQ Composite

26,090.73

−134.41

-0.51%

Russell 2000

2,775.10

−18.20

-0.65%

VIX

17.82

−0.61

-3.31%

Biggest Gainers

Mon, May 18, 2026 50

AMPGR

Amplitech Group, Inc. Series A Right

$0.25+$0.19

+350.0%

NASDAQ

A single positive analyst note on AmpliTech's growth prospects was published May 17th; however, the 350% jump in the Series A Right security suggests either leveraged amplification of the underlying stock move or a technical catalyst unrelated to the headline, as rights instruments are highly vol…

The only recent headline is a May 17th analyst commentary stating AmpliTech is "in a good position to deliver on growth plans," with the article appearing to be a general bullish take on unprofitable tech companies using Amazon as a comparison. This is a relatively soft catalyst and unlikely to drive a 350% single-day move on its own. However, AMPGR is a Series A Right, a derivative security that typically trades with extreme volatility and can amplify moves in the underlying common stock. If the underlying AMPG stock experienced a significant rally on May 17th-18th, the rights could have jumped substantially more. The move could also reflect a technical bounce from depressed levels, short covering, or other factors entirely unrelated to the published headline. The illiquid nature of rights securities means single trades can create outsized percentage swings.

AMPGZ

Amplitech Group, Inc. Series B Right

$0.25+$0.15

+150.0%

NASDAQ

A single bullish analyst note on May 17th suggesting AmpliTech is well-positioned for growth likely triggered the 150% surge in the Series B rights offering, which trades with extreme volatility due to its small float and speculative nature.

The only headline provided is an analyst commentary from May 17th stating AmpliTech is in a good position to deliver on growth plans, with a comparison to Amazon's path to profitability. This is not a hard catalyst like earnings or guidance but rather a positive sentiment piece. However, AMPGZ is a Series B rights offering, a derivative security that can exhibit outsized moves on modest news due to extremely low trading volume and float. Rights offerings trade with high leverage to underlying sentiment shifts. The 150% move is plausible for a micro-cap rights vehicle responding to renewed bullish commentary on the parent company (AMPG). Without additional headlines or news flow, we cannot rule out technical factors like short covering, option mechanics, or delayed dissemination of other announcements, but the timing aligns with the May 17th analyst note.

WGRX

Wellgistics Health, Inc.Healthcare

$0.17+$0.09

+108.4%

NASDAQ · Mkt cap $157 M

No news headlines were found in the last 48 hours to explain the 108% surge in WGRX stock price, so the catalyst remains unclear from publicly available information.

Wellgistics Health (WGRX) nearly doubled on May 18, 2026, but no recent news announcements appear in the Yahoo Finance feed within the relevant timeframe. For a micro-cap healthcare stock trading at $0.17, such a move could plausibly stem from several categories of event: a delayed earnings release or clinical trial announcement not yet indexed by the RSS feed, short covering or technical buying in a thinly traded security, an unverified rumor circulating on social media or message boards, insider activity, or a corporate announcement made through channels not captured by Yahoo Finance's feed at the snapshot time. Without access to company filings, press releases, or broader news archives, we cannot establish which of these mechanisms actually drove the move. The absence of corroborating headlines is notable and suggests either a very recent announcement still propagating through news aggregators, or a catalyst that hasn't yet received mainstream coverage.

HCAI

Hauchen AI Parking Management Technology Holding Co., Ltd.Industrials

$11.00+$5.46

+98.6%

NASDAQ · Mkt cap $7.9 M

No relevant headlines were found in the last 48 hours to explain the 98.56% jump in HCAI stock, suggesting the move was driven by factors other than reported company news.

The absence of any news headlines in the provided RSS feed within the last 48 hours means we cannot attribute this nearly doubling of the stock price to a specific announced event such as earnings, partnership, regulatory approval, or guidance revision. For a microcap or lower-liquidity stock like a parking management technology company trading on NASDAQ, large intraday moves can be triggered by several categories of catalyst: technical factors such as short covering or momentum trading in a thinly traded name, delayed or unindexed news that reached retail investors through non-RSS channels, social media discussion, or changes in analyst coverage. Without access to after-hours trading data, SEC filings, or news sources beyond the provided RSS feed, we cannot determine which mechanism drove this specific move. The stock's rank as the fourth biggest gainer suggests this was a broad market event rather than isolated noise.

GOVX

GeoVax Labs, Inc.Healthcare

$2.21+$0.98

+79.7%

NASDAQ · Mkt cap $3.1 M

GeoVax announced a $3 million private placement financing and issued a press release highlighting the strategic importance of its MVA-based vaccine platform amid WHO declarations of Ebola and ongoing Mpox threats, likely driving investor confidence in near-term commercial relevance.

The 79.67% single-day jump coincides with two material announcements on May 18th. First, GeoVax secured $3 million in at-the-market private placement financing, which provides near-term capital for operations. Second, and more significantly, the company released a strategic commentary tying its existing MVA vaccine platform directly to two active global health emergencies: a WHO-declared Ebola outbreak and ongoing Mpox developments. For a clinical-stage biotech with limited revenue, these headlines reframe the company's vaccine technology as addressing immediate geopolitical and epidemiological urgency rather than hypothetical future markets. This combination of fresh capital and validation of platform relevance through real-world disease activity appears sufficient to drive speculative buying and short covering, particularly in a small-cap stock where sentiment shifts can produce outsized price moves.

SBFM

Sunshine Biopharma, Inc.Healthcare

$0.51+$0.23

+79.5%

NASDAQ · Mkt cap $4.5 M

Sunshine Biopharma announced a $6.0 million public offering priced on May 18, likely triggering a 79.51% single-day rally driven by positive sentiment around funding and pipeline advancement in oncology and antivirals.

The headline confirms that Sunshine Biopharma priced a $6.0 million public offering on the same date as the stock's 79.51% jump. For micro-cap and small-cap biotech companies, capital raises often signal management confidence in pipeline assets and near-term catalysts. The offering itself is relatively modest in absolute dollars, but for a stock trading at $0.51, it may represent meaningful dilution or, conversely, a vote of confidence if the raise supports clinical development or regulatory milestones in oncology or antivirals. The timing and magnitude of the move—rank 6 gainer—suggests retail or institutional buying enthusiasm tied to the announcement. However, the headline provided is truncated and does not detail pricing per share, terms, use of proceeds, or any clinical updates, limiting precision in cause attribution.

AIM

AIM ImmunoTech Inc.Healthcare

$0.41+$0.16

+61.3%

AMEX · Mkt cap $7.3 M

No news headlines were found in the last 48 hours, so the 61% gain on May 18 cannot be directly attributed to a reported corporate event. The move likely reflects either a technical or sentiment-driven catalyst undetected in the available news feed.

AIM ImmunoTech is a small-cap biotech stock trading on AMEX at a low share price, a profile typical of high-volatility, speculative securities. The absence of any news in the Yahoo Finance RSS over the past 48 hours is notable and suggests the catalyst was either not yet widely reported at the time of the snapshot, driven by social media or retail trader activity, or tied to a technical event such as short covering or option expiration dynamics. Small-cap biotech stocks with minimal public float or high short interest can experience sharp intraday rallies on modest volume shifts or sentiment changes unrelated to fundamental news. Without evidence of earnings, clinical trial results, regulatory filings, partnerships, or other concrete corporate developments, we cannot pinpoint a specific driver and must treat this as a category of move driven by factors outside the traditional news cycle.

VRAX

Virax Biolabs Group LimitedHealthcare

$0.24+$0.08

+53.1%

NASDAQ · Mkt cap $2.5 M

No news was found in the last 48 hours to explain the 53% surge in VRAX stock price, suggesting the move may be driven by technical factors, delayed announcements, or market rumors rather than confirmed corporate developments.

The absence of any headlines in the Yahoo Finance RSS feed over the past 48 hours is notable given the magnitude of the price movement. VRAX is a small-cap biotech company, and stocks in this category are often susceptible to technical rallies, short covering, or retail interest based on social media activity rather than fundamental catalysts. The 53% single-day gain could reflect accumulating buying pressure from options activity, a delayed announcement not yet widely indexed, or broader sector momentum in biotech. Without access to real-time news, regulatory filings, or institutional activity data, it is impossible to identify the specific trigger. The stock's low absolute price of $0.24 suggests it may be a penny stock or post-bankruptcy restructuring play, both of which are prone to volatile swings on minimal volume or speculative positioning.

NXXT

NextNRG Inc.Utilities

$0.41+$0.13

+46.2%

NASDAQ · Mkt cap $40 M

NextNRG reported 195% revenue growth in Q1 2026 earnings released on May 18, which appears to have driven the 46% intraday surge, though the stock faces ongoing liquidity and net loss headwinds that temper the enthusiasm.

The earnings call highlights released on May 18 reveal that NextNRG achieved exceptional revenue growth of 195% year-over-year, which represents a material operational milestone for the renewable energy company and likely triggered the substantial single-day gain. However, the same earnings announcement explicitly notes the company faces liquidity constraints and ongoing net losses despite the revenue expansion. An analyst report from May 17 also cited the stock's claimed upside potential of 1624%, suggesting market optimism was already building pre-earnings. The disconnect between strong top-line growth and financial stress (cash constraints, unprofitability) suggests the market is pricing in future profitability and growth potential rather than current financial health. Without knowing the exact earnings surprise magnitude, guidance changes, or specific contract wins mentioned in the call, we cannot isolate whether the move reflects a beat-versus-consensus or simply execution on previously telegraphed growth.

RIBBR

Ribbon Acquisition Corp Rights

$0.33+$0.10

+43.4%

NASDAQ · Mkt cap $1.2 M

No news headlines were found in the last 48 hours, so the 43% jump in RIBBR rights shares likely reflects either a broader market move in the underlying SPAC, technical trading activity, or unreported corporate event.

Ribbon Acquisition Corp Rights are derivative securities tied to the parent SPAC's warrant or share activity, meaning they can move sharply on SPAC-specific catalysts even without mainstream news coverage. The absence of Yahoo Finance headlines does not rule out material developments: SPAC announcements, insider trades, redemption activity, or movement toward a merger deadline often drive intraday spikes in rights instruments. Rights also exhibit thin liquidity and high volatility, making them susceptible to technical momentum or retail trading surges. A 43% single-day gain in a low-priced rights offering could reflect justified fundamental news (deal progress, sponsor commitment) or pure speculative positioning; without news confirmation, the root cause remains unclear.

GCTS

GCT Semiconductor Holding, Inc.Technology

$2.58+$0.75

+41.0%

NYSE · Mkt cap $182 M

No news headlines were found in the last 48 hours, so the 41% gain likely stems from technical factors, short-covering, delayed announcements, or market rumors not captured in the available news feed.

GCTS experienced a substantial single-day gain of over 40%, ranking it among the top gainers on 2026-05-18, yet no news headlines appear in the Yahoo Finance RSS feed for the preceding 48 hours. This disconnect suggests the catalyst was either not yet formally published by major outlets, emerged from non-traditional sources such as social media or specialized trading forums, or represents a technical event like short squeeze activity or options expiration effects. For a small-cap semiconductor company like GCT Semiconductor, potential drivers could include positive developments in their core products or partnerships, short-squeeze momentum if the stock had elevated short interest, or reactive buying following an earnings report or company announcement released outside the headline window examined here. Without concrete news to anchor the analysis, the true cause remains speculative.

AIIO

Robo.ai Inc.Consumer Cyclical

$5.60+$1.58

+39.3%

NASDAQ · Mkt cap $487 M

Robo.ai's subsidiary Neurovia AI announced its debut at a major international exhibition on national security in Abu Dhabi, likely attracting investor interest in the company's government and defense sector positioning, driving the 39% gain.

The sole headline from the past 48 hours reports that Neurovia AI, a subsidiary of Robo.ai, is making its inaugural appearance at the 9th International Exhibition for National Security and Resilience in Abu Dhabi on 2026-05-18. While the announcement itself is relatively modest in scope—essentially a trade show debut—it signals the company's entry into or expansion within the national security and defense infrastructure markets, which are typically high-margin and strategically valuable segments. For a smaller-cap stock like AIIO trading at $5.60, visibility at a prestigious international security conference can generate significant retail and institutional interest, particularly if investors perceive it as validation of the subsidiary's technology or market positioning. However, the headline provides no specific contract wins, revenue figures, or forward guidance that would independently justify a 39% intraday move, suggesting the market reaction may be outsized relative to the concrete information disclosed.

SACH

Sachem Capital Corp.Real Estate

$1.40+$0.37

+35.9%

AMEX · Mkt cap $38 M

Sachem Capital announced a strategic combination with Industrial Realty Group to create IRG Realty Trust, a top-10 public industrial REIT, which likely drove the 35.92% gain as investors revalued the company in light of this transformational merger.

The headline directly announces a major strategic transaction: Sachem Capital is combining with Industrial Realty Group to form what will be a top-10 public industrial REIT. This is a significant corporate action that fundamentally changes the company's profile from a specialty real estate lender into a REIT with presumably broader asset scale and market positioning. Investors typically respond sharply to M&A announcements involving publicly traded companies, especially when the deal creates an enlarged entity positioned to compete in a major category. The 35.92% one-day gain is consistent with a positive market reception to the deal terms, the strategic rationale, or both. The headline is dated the same day as the price snapshot, establishing clear temporal alignment between the announcement and the move.

TOP

TOP Financial Group LimitedFinancial Services

$1.07+$0.25

+30.7%

NASDAQ · Mkt cap $1.4 B

No news headlines were found in the last 48 hours for TOP Financial Group Limited, so the 30.66% gain cannot be attributed to a specific announced event. The jump likely reflects technical trading, short covering, or delayed market reaction to older news.

The absence of recent headlines makes pinpointing the cause difficult. TOP is a small-cap financial services stock trading at $1.07, which typically exhibits higher volatility than large-cap peers. A 30% single-day move in this price range can result from several mechanisms: short squeezes in thinly traded stocks, technical breakouts above resistance levels, retail trading bursts on social media, or delayed market digestion of company announcements published more than 48 hours ago. Without access to intraday volume data, options activity, or broader market context on May 18, 2026, we cannot determine whether this was driven by company-specific factors or momentum-based trading. It is also possible that material news was released outside the Yahoo Finance RSS feed monitored here.

CREG

Smart Powerr Corp.Utilities

$0.62+$0.15

+30.6%

NASDAQ · Mkt cap $499 K

No news headlines were available in the last 48 hours to explain the 30.59% jump in CREG stock. The move was likely driven by technical factors, retail trading activity, or undisclosed company developments not yet reflected in major news feeds.

Smart Powerr Corp. (CREG) posted a significant one-day gain while ranking as the fifteenth biggest mover on NASDAQ, yet no material news headlines appeared in the last two days to explain the price action. This disconnect is common in micro-cap and penny stocks, which can experience sharp moves on limited volume, short covering, options-driven activity, or social media-driven retail interest. Without access to press releases, earnings reports, regulatory filings, or company announcements that may have been distributed through non-syndicated channels, we cannot identify a specific catalyst. The most probable categories are technical momentum, a delayed market reaction to news published earlier than 48 hours ago, or developments announced through channels not captured by standard financial news RSS feeds.

WFCF

Where Food Comes From, Inc.Industrials

$11.93+$2.71

+29.3%

NASDAQ · Mkt cap $62 M

No news headlines were found in the last 48 hours for WFCF, so the 29.32% gain likely reflects a technical bounce, delayed news pickup, or market speculation rather than a confirmed corporate event.

The absence of recent headlines is notable given the magnitude of the move. WFCF is a small-cap food traceability and verification company, and such stocks can be volatile on thin trading volume. The jump could stem from several sources: a press release or filing that has not yet been picked up by Yahoo Finance RSS, short covering if the stock has high short interest, a positive analyst note or upgrade without full distribution, renewed investor interest in food-safety or supply-chain stocks as a sector, or simply a technical rebound after a prior decline. Without confirming news, attributing the move to any specific catalyst would be speculation. Small-cap stocks in this space sometimes experience outsized single-day moves on modest volume shifts or sentiment changes that precede formal announcements.

HIVE

HIVE Digital Technologies Ltd.Financial Services

$3.46+$0.77

+28.6%

NASDAQ · Mkt cap $820 M

HIVE Digital surged 28.62% on announcement that its BUZZ HPC subsidiary plans a 320 MW AI data center near Toronto with a $3.5 billion investment, plus a fiber upgrade contract at its Grand Falls facility.

The headlines establish a clear catalyst: on May 18, HIVE announced two infrastructure developments. The primary driver appears to be BUZZ HPC's unveiling of a planned 320 megawatt AI facility near Toronto representing a $3.5 billion investment, one of Canada's largest AI data centers. This addresses strong market demand for AI compute infrastructure and positions HIVE as a significant player in that space. A secondary catalyst was BUZZ HPC's contracting of a fiber network upgrade at the Grand Falls data center, supported by a recent $115 million zero-percent exchangeable note. The stock's 34 percent intraday peak suggests the AI gigafactory announcement drove outsized enthusiasm, likely reflecting investor appetite for AI infrastructure exposure and confidence in HIVE's ability to capitalize on the AI compute buildout trend.

SEGG

Sports Entertainment Gaming Global CorporationConsumer Cyclical

$2.40+$0.53

+28.3%

NASDAQ · Mkt cap $8.4 M

No news headlines were found in the last 48 hours, so the 28% gain cannot be attributed to a specific announced event. The jump likely reflects either technical trading, a delayed news pickup, or market speculation related to the sports gaming sector.

The absence of recent headlines makes it difficult to pinpoint a single catalyst for SEGG's strong 28% intraday move. This is a small-cap gaming and entertainment stock, and securities in this category can be volatile and reactive to sector sentiment, short-covering, or rumors that may not yet be reflected in major financial news feeds. The stock's low absolute price of $2.40 also makes it susceptible to retail trading activity and technical breakouts. Possible explanations include a positive earnings surprise or guidance revision that hasn't yet propagated to Yahoo Finance's RSS feed, a regulatory or licensing development in gaming jurisdictions, or simply a momentum-driven rally driven by technical factors or social media chatter. Without headline confirmation, however, these remain speculative categories rather than identified causes.

RAMP

LiveRamp Holdings, Inc.Technology

$37.77+$8.11

+27.3%

NYSE · Mkt cap $2.3 B

French advertising company Publicis announced a $2.2 billion acquisition of LiveRamp on May 18, directly triggering the 27% jump in stock price.

The headline evidence is unambiguous. At 14:16 UTC on May 18, Yahoo Finance reported that LiveRamp stock surged 27% following Publicis's announcement of a definitive agreement to acquire the U.S. data specialist for $2.2 billion. A separate headline from 12:47 UTC corroborates this, noting that shares surged more than 26% in premarket trading after LiveRamp reported stronger-than-expected fourth-quarter earnings AND announced the acquisition deal. The timing aligns perfectly: the premarket surge preceded the official market open, and by late afternoon, the full 27% gain was recorded. While the broader tech sector faced headwinds on May 18 (multiple headlines note tech stocks fell Monday afternoon and crude oil price rebounds pressured equities), RAMP's exceptional outperformance is directly attributable to the M&A announcement and earnings beat, both of which represent company-specific positive catalysts that override sector sentiment.

Chaince Digital Holdings Inc.Financial Services

$10.49+$2.20

+26.5%

NASDAQ · Mkt cap $436 M

No news headlines were found in the last 48 hours for CD, so the 26.54% gain likely reflects a technical rebound, market rotation, or undisclosed catalyst that has not yet appeared in major news feeds.

The absence of any Yahoo Finance headlines in the 48-hour window surrounding this significant single-day gain makes it impossible to attribute the move to a specific fundamental event such as earnings, product announcement, or corporate action. For a microcap or lower-liquidity stock like CD, large percentage moves can result from several categories of catalyst that may not generate immediate press coverage: technical oversold conditions triggering short-covering or algorithmic buying, retail investor coordination through social media or chat platforms, sector rotation into digital or blockchain-related names, or simply thin-float dynamics where modest volume produces outsized percentage moves. Without access to intra-day volume data, order flow, or insider filings from the snapshot date, attributing causation would be speculation.

FATN

FatPipe, Inc. Common StockTechnology

$5.15+$1.05

+25.6%

NASDAQ · Mkt cap $86 M

FatPipe reported strong Q4 and full-year 2026 results with 90% Y-o-Y Q4 revenue growth and 56% Y-o-Y recurring revenue growth, which likely triggered the 25.6% gain as investors responded positively to the earnings beat.

FatPipe released Q4 and fiscal year 2026 earnings results on May 18, 2026, showing substantial revenue acceleration in the quarter with 90% year-over-year growth and recurring revenue up 56% year-over-year, alongside annual revenue growth of 18%. These metrics suggest the company is expanding its SD-WAN and cybersecurity solutions at an accelerating rate, particularly in the high-margin recurring revenue segment. The substantial outperformance in Q4 relative to full-year growth implies positive momentum into the new fiscal year. Investors appear to have rewarded these results with a sharp intraday rally. Without access to guidance, analyst estimates, or profit margins, we cannot determine whether this was a beat-versus-expectations event or simply a market revaluation based on the absolute growth metrics disclosed.

AMPG

AmpliTech Group, Inc.Technology

$3.70+$0.75

+25.4%

NASDAQ · Mkt cap $107 M

A single analyst article titled "AmpliTech Group (NASDAQ:AMPG) Is In A Good Position To Deliver On Growth Plans" published on May 17 likely drove the 25% rally, though the headline excerpt provided does not reveal the specific catalysts or reasons cited in the full analysis.

The only headline available is an analyst commentary piece from May 17 that frames AmpliTech positively relative to its growth prospects, referencing unprofitable companies like Amazon that can still create shareholder value. The snippet does not detail what specific operational improvements, contract wins, strategic shifts, or financial milestones prompted this optimistic reassessment. For a micro-cap stock trading at $3.70 with limited institutional coverage, a single bullish analyst piece or shift in sentiment can trigger outsized percentage moves, especially if short interest or low float amplifies the move. Without the full article text or corroborating news, the precise catalyst remains unclear, though the timing and magnitude suggest investor response to the analyst's positive thesis on execution of growth plans.

SMTK

SmartKem, Inc.Technology

$0.28+$0.05

+24.7%

NASDAQ · Mkt cap $2.2 M

No news headlines were found in the last 48 hours, so the 24.73% gain cannot be attributed to a specific disclosed catalyst. The move likely reflects technical trading, speculative interest in a micro-cap stock, or an undisclosed event.

SmartKem is a small-cap semiconductor company trading at $0.28 with minimal liquidity typical of stocks in this price range. The absence of any news headlines in the past 48 hours means no earnings announcement, partnership, FDA approval, or guidance change can be documented as the cause. Micro-cap stocks of this type often experience large percentage swings on relatively small absolute dollar volume, driven by technical factors such as short covering, algorithmic trading, options expiration effects, or retail investor interest. Alternatively, the catalyst could be a delayed news announcement not yet indexed by Yahoo Finance, internal company news released through non-standard channels, or pure sentiment-driven speculation. Without access to intraday volume data, trading patterns, or broader market catalysts, any specific cause remains speculative.

MPU

Mega Matrix Corp.Communication Services

$0.62+$0.12

+24.7%

AMEX · Mkt cap $14 M

No news headlines were found in the last 48 hours, so the 24.66% gain cannot be directly attributed to a published announcement. The jump may reflect technical trading activity, delayed reporting of company news, or market speculation in a low-priced stock.

The absence of recent headlines creates genuine uncertainty about the catalyst. MPU is trading at $0.62, which places it in the micro-cap or penny-stock category where price swings are often driven by factors other than traditional news dissemination. Possible explanations include a delayed press release not yet indexed by major financial RSS feeds, short covering by momentum traders, retail investor social media interest, or technical breakout above a resistance level. Without corroborating news, company guidance, earnings reports, or other documented events, any specific claim about causation would be speculation rather than evidence-based analysis.

AIB

BlockchAIn Digital Infrastructure, Inc.Technology

$1.79+$0.35

+24.3%

T1 Energy IncIndustrials

$7.00+$1.33

+23.5%

NYSE · Mkt cap $1.3 B

T1 Energy jumped 23.46% following social media buzz around a 13-F disclosure mentioning the stock, likely connected to high-profile investor activity in the energy/Bitcoin mining sector highlighted by HIVE Digital's 34% gain on the same catalyst.

The headline indicates that both HIVE Digital and T1 Energy surged on May 18th following a wave of social media buzz triggered by a 13-F filing disclosure. The incomplete headline references "Aschenbrenner Buzz," suggesting a notable investor or analyst commentary drove attention to these stocks. The fact that HIVE (a Bitcoin mining company) gained 34% on the same day and the same catalyst strongly implies this was sector-wide enthusiasm, possibly tied to cryptocurrency or energy sector positioning. T1 Energy's 20% gain mentioned in the headline aligns closely with the reported 23.46% move, confirming the timing. However, the headline is truncated and does not provide the full details of what the 13-F disclosure contained or who specifically drove the "buzz." The connection between these two stocks suggests institutional positioning or a notable investor bet on the energy/mining space.

ZETX

Daily Target 2X Long ZETA ETF

$19.31+$3.61

+23.0%

AMEX

No news was reported in the last 48 hours, but ZETX is a 2X leveraged long ETF tracking ZETA, so a ~11.5% gain in the underlying would mechanically produce this ~23% move; the underlying catalyst remains unknown.

Yahoo Finance returned no headlines for ZETX or likely its underlying asset ZETA in the last two days. However, ZETX is a daily target 2X leveraged long ETF, meaning it amplifies the daily moves of its benchmark by roughly a factor of two. A 22.99% one-day gain in a 2X leveraged product is consistent with an ~11.5% gain in the underlying security. Without access to news on ZETA itself or real-time market data on the underlying, we cannot determine what drove that move—it could reflect earnings, guidance, sector rotation, technical rebound, or other market-moving events. The leverage structure explains the magnitude but not the source.

ZDAI

DirectBooking Technology Co., Ltd.Industrials

$1.78+$0.33

+22.8%

NASDAQ · Mkt cap $13 M

No news headlines were found in the last 48 hours, so the 22.76% gain likely reflects either delayed market reaction to an earlier announcement, a technical bounce, or investor sentiment shift that has not yet been covered by major news outlets.

The absence of recent news headlines creates a challenge in identifying the specific catalyst for ZDAI's 22.76% jump. DirectBooking Technology operates in the travel and hospitality technology sector, which can be sensitive to booking trends, partnership announcements, or operational milestones. Without headline confirmation, the move could reflect several plausible categories: a delayed market reaction to news released before the 48-hour window, short-covering or technical momentum given the stock's position as a mid-tier gainer, or investor optimism tied to industry trends or earnings expectations not yet formally announced. Smaller-cap NASDAQ names like this sometimes experience outsized intraday moves on light volume or sector rotation. However, without substantive supporting news, any specific explanation remains speculative.

GENI

Genius Sports LimitedCommunication Services

$5.18+$0.94

+22.2%

NYSE · Mkt cap $2.2 B

No news headlines are available for the last 48 hours, so the 22% gain cannot be attributed to a specific announced catalyst. The move likely reflects technical momentum, short covering, or market speculation without confirmed fundamental drivers.

Genius Sports Limited (GENI) rose 22.17% to rank as the 29th biggest gainer on May 18, 2026, but no news articles appear in the Yahoo Finance RSS feed for the preceding 48 hours. This absence of contemporaneous headlines means we cannot point to earnings, guidance, partnerships, regulatory approvals, or management changes as the stated cause. For a sports gaming and betting analytics company like GENI, typical catalysts would include sportsbook partnerships, international expansion announcements, or quarterly beat results. Without confirmed news, the jump is most plausibly attributable to technical factors such as short covering in a thinly traded name, options-driven demand, or market speculation ahead of an unannounced event. Retail trader attention or momentum chasing is also possible. The lack of evidence prevents a higher-confidence attribution.

ATER

Aterian, Inc.Consumer Cyclical

$1.33+$0.24

+22.0%

NASDAQ · Mkt cap $5.0 M

No news headlines were reported in the last 48 hours for ATER, so the 22% intraday gain likely stems from technical factors, delayed news coverage, or market rumors rather than a confirmed corporate announcement.

The absence of any Yahoo Finance headlines in the past two days makes it difficult to pinpoint a specific catalyst for ATER's strong 22% move on May 18, 2026. Aterian is a small-cap consumer products and e-commerce company, which means it is susceptible to technical volatility, short-squeeze activity, retail trading interest, and delayed news dissemination. Without corroborating headlines, possible explanations include a positive earnings surprise or guidance revision that has not yet been widely reported, insider buying or analyst upgrades circulating before formal announcements, or momentum-driven trading in response to technical levels or short covering. The lack of news coverage does not rule out a real business event; it simply means the evidence provided does not confirm it.

RVPH

Reviva Pharmaceuticals Holdings, Inc.Healthcare

$0.40+$0.07

+22.0%

NASDAQ · Mkt cap $6.6 M

Reviva announced participation in A.G.P.'s Annual Healthcare Company Showcase on May 18, likely driving modest investor interest in the microcap stock, though the headline offers limited concrete catalysts for the 22% jump.

The sole headline documents Reviva's participation in a fireside chat at A.G.P.'s healthcare showcase on May 18, the same date as the price move. While investor conferences can raise awareness of small-cap pharmaceutical companies, this announcement alone—a brief participation notice with no clinical trial results, FDA decisions, partnerships, or financial guidance—typically does not generate a 22% single-day rally on its own. The move suggests either (1) the market had already priced in negative sentiment and this visibility event triggered technical mean reversion or covering of shorts, (2) an undisclosed detail from the actual presentation at the showcase drove buying, or (3) coincidental technical momentum in a thinly traded OTC-listed stock unrelated to this event. For a late-stage pharma microcap trading at $0.40, volume spikes and low float can amplify moves significantly without fundamental justification.

VUZI

Vuzix CorporationTechnology

$3.65+$0.65

+21.7%

NASDAQ · Mkt cap $260 M

No news headlines were found in the last 48 hours, so the 21.67% gain cannot be tied to a specific announced event. The jump likely stems from technical trading, delayed news dissemination, or market rumors about Vuzix.

Vuzix Corporation is a small-cap AR/VR hardware and software company historically prone to significant daily volatility and retail investor interest. With zero headlines in the provided 48-hour window despite a top-32 gainer ranking, the catalyst remains opaque. Possible explanations include: first, a technical or short-squeeze trigger in a thinly-traded stock with high short interest, which can generate outsized moves on modest volume; second, news that circulated on social media or specialized forums before reaching mainstream financial RSS feeds; or third, a delayed or embargoed announcement not yet indexed in the headline source. Without confirmation of a specific catalyst, attributing this move to fundamentals is premature.

GGRP

The Glimpse Group, Inc.Technology

$0.79+$0.14

+21.7%

NASDAQ · Mkt cap $20 M

No news headlines were available in the last 48 hours, so the 21.65% gain likely reflects either delayed market reaction to an announcement, technical trading activity, or microstock volatility common to low-priced NASDAQ stocks.

The Glimpse Group is a micro-cap stock trading at $0.79 with no recent news coverage identified in the Yahoo Finance RSS feed over the past two days. Without specific catalyst information, the jump could stem from several sources typical for stocks in this price range: delayed market recognition of a prior announcement not yet indexed by the feed, short-covering or technical momentum in a thinly traded name, sector rotation into extended reality or metaverse-related plays if GGRP operates in that space, or investor accumulation based on private information not yet public. Stocks this small also exhibit significant volatility from low absolute dollar volume moves. Without confirming headlines or structural details, attribution remains speculative.

COOK

Traeger, Inc.Consumer Cyclical

$49.43+$8.69

+21.3%

NYSE · Mkt cap $164 M

No news headlines were found in the last 48 hours, so the 21.33% jump in COOK stock on May 18, 2026 cannot be attributed to a specific reported event based on available information.

Traeger Inc. experienced a significant one-day gain of over 21 percent with no accompanying news coverage in the recent news feed. This disconnect suggests the catalyst may be either unreported at the time of data collection, a technical or market-driven event, or news that broke outside standard financial media channels. For a consumer discretionary stock like Traeger, typical catalysts that drive large single-day moves include quarterly earnings surprises, analyst upgrades or rating changes, short covering activity, broad sector rotation into consumer stocks, or executive announcements. Without headline confirmation, it is impossible to determine which of these mechanisms, if any, drove today's movement. The absence of news makes this move difficult to rationalize from a fundamental perspective.

TTRX

Turn Therapeutics Inc.Healthcare

$4.90+$0.85

+21.0%

NASDAQ · Mkt cap $295 M

Turn Therapeutics appointed Dr. Stephen M. Hahn, former FDA Commissioner, as Executive Clinical and Regulatory Lead, a high-profile hire that likely drove the 21% gain by signaling stronger regulatory credibility and pathway clarity for its skin disease therapies.

The company announced the appointment of Dr. Stephen M. Hahn, a physician-scientist and former FDA Commissioner, to a newly created executive role focused on clinical and regulatory strategy. This is a materially significant hire for a clinical-stage biotech company because it directly addresses investor concerns about regulatory navigation and approval pathways. A former FDA head brings credibility, internal knowledge of the agency, and market perception of de-risking the development program. For a smaller biotech stock trading at $4.90, such an appointment signals management confidence in advancing its inflammatory skin disease pipeline and can substantially improve institutional investor sentiment. The timing and prominence of the announcement in financial media on the same day as the price jump strongly suggest causality between the hiring news and the equity appreciation.

AUUD

Auddia Inc.Technology

$2.37+$0.41

+20.9%

NASDAQ · Mkt cap $5.5 M

Auddia announced new market pricing benchmarks for its LT350 AI infrastructure platform, revealing a $1.25B GPU cloud contract and implying $30,488 annual revenue per GPU, which likely triggered the 21% rally as evidence of substantial commercial traction.

The headline establishes that Auddia disclosed market pricing data derived from a SharonAI filing showing concrete contract economics for GPU cloud services. The $1.25B five-year contract value and per-GPU revenue implications suggest meaningful revenue visibility and commercialization progress. The reference to a previously disclosed LT350 REIT partnership supporting up to 960,000 GPUs indicates potential for massive scale. For a small-cap stock like Auddia trading at $2.37, this kind of quantified proof of market demand and contract value typically catalyzes significant intraday rallies, particularly in the AI infrastructure space where investor appetite remains elevated. The timing and specificity of the benchmark data release appears to be the direct trigger for today's move.

NFT LimitedConsumer Cyclical

$18.90+$3.23

+20.6%

AMEX · Mkt cap $1.6 M

No news headlines were found in the last 48 hours, so the 20.6% rally cannot be attributed to a documented announcement or earnings event, leaving the driver unclear.

MI (NFT Limited) jumped 20.6% to rank as the 37th biggest gainer of the day, yet no news articles appeared in the Yahoo Finance RSS feed in the preceding 48 hours. This absence of documented headlines means the move likely stems from one of several unstated causes: a technical or momentum-driven spike common in lower-volume or highly volatile securities, an announcement released outside the RSS feed window, broker upgrades or social media chatter that spread without major press coverage, or broader sector rotation. NFT and crypto-adjacent equities have shown sensitivity to sentiment swings and retail interest, but without headlines the specific catalyst remains a matter of inference rather than fact. The timing and magnitude suggest either a delayed market reaction to earlier news, intraday technical breakout, or undocumented event.

PPCB

Propanc Biopharma, Inc.Healthcare

$2.05+$0.35

+20.6%

NASDAQ · Mkt cap $2.6 M

No news headlines were found in the last 48 hours, so the 20.59% jump on PPCB likely stems from technical trading, a delayed news event, or market speculation unconfirmed by public sources.

Propanc Biopharma is a development-stage biotech company focused on cancer treatment candidates, making it inherently volatile and susceptible to moves on limited information. The absence of news in the provided feed does not mean no catalyst occurred; the move could reflect delayed market reaction to an earlier announcement, insider activity becoming public, clinical trial progress expectations, or sector-wide biotech momentum. Small-cap biotech stocks frequently experience sharp intraday moves on relatively light volume, and PPCB's rank as the 38th biggest gainer suggests genuine but localized interest rather than broad market rotation. Without confirming headlines, the driver remains speculative.

CVM

CEL-SCI CorporationHealthcare

$1.72+$0.29

+20.3%

OSCG

Leverage Shares 2x Long OSCR Daily ETF

$22.89+$3.69

+19.2%

NASDAQ

No news headlines were found in the last 48 hours, but the +19.24% gain is likely explained by a sharp rally in the underlying OSCR security, which this 2x leveraged ETF amplifies by design.

The absence of recent news headlines for OSCG itself does not preclude a significant move, because this security is a 2x leveraged daily ETF tracking the underlying OSCR. If OSCR gained roughly 9-10% on the day, OSCG would mechanically amplify that into a ~19% move through its leverage structure. The gain is consistent with ordinary leverage mechanics rather than an isolated catalyst affecting the fund itself. To identify the true cause, one would need to examine news and price action for the underlying OSCR security, which is not provided here. Without visibility into OSCR's own headlines or market events, the most probable explanation is straightforward leverage amplification of an underlying rally, though the specific catalyst for that rally remains unknown.

ASBP

Aspire Biopharma Holdings, Inc.Healthcare

$6.68+$1.07

+19.1%

NASDAQ · Mkt cap $10 M

No news headlines were available in the last 48 hours, so the 19% gain on May 18, 2026 cannot be attributed to a specific announced event; the catalyst is unknown but may involve clinical trial results, partnership news, or technical trading activity typical of small-cap biotech stocks.

The absence of any headlines in the Yahoo Finance RSS feed within the last 48 hours means we cannot anchor the move to a specific corporate announcement, regulatory action, or market event. For a small-cap biopharmaceutical company like Aspire Biopharma, strong single-day gains of this magnitude typically correlate with clinical trial data releases, FDA decisions, licensing agreements, or major partnership announcements—all events that would normally generate immediate press coverage. It is also possible that news was released outside the monitored window, that coverage was delayed, or that the move reflects technical factors such as short covering, options expiration dynamics, or accumulation by institutional buyers. Without documented headlines, attribution remains speculative.

BRC

Brady CorporationIndustrials

$84.43+$13.47

+19.0%

NYSE · Mkt cap $4.3 B

Brady Corporation surged 19% after reporting third-quarter earnings that beat expectations, posting record adjusted EPS and 8.2% organic sales growth, while also raising full-year guidance and benefiting from strength in data center identification solutions tied to AI infrastructure demand.

The headlines establish a multi-part positive catalyst on May 18. Brady reported Q3 2026 earnings ahead of Wall Street expectations with revenue of $435.2 million (up 13.8% year-over-year), record adjusted earnings per share, and gross margin near 52%. Management raised full-year adjusted EPS guidance. The CEO called it a "fantastic quarter" with broad-based organic sales growth of 8.2% and strong profitability gains across both regions. Additionally, one headline explicitly ties part of the strength to Brady's role in data center optimization, framing this as AI-related exposure. The combination of an earnings beat, raised guidance, and a narrative connecting the company to the current AI infrastructure tailwind appears sufficient to explain the magnitude of the move. The stock rallied approximately 6% in premarket before opening and continuing higher.

YMT

Yimutian Inc. American Depositary SharesTechnology

$2.20+$0.35

+18.9%

NASDAQ · Mkt cap $2.3 M

No news headlines were found in the last 48 hours, so the 18.88% gain on YMT cannot be attributed to a specific announcement or earnings release; the cause likely falls into technical, delayed news, or retail trading activity.

The absence of recent Yahoo Finance headlines is notable given the magnitude of the move. YMT, a small-cap American Depositary Share listed on NASDAQ, experienced a substantial single-day gain that ranks among the top 50 movers. Without corresponding news in the RSS feed, several categories of catalyst are plausible: a delayed or embargoed announcement not yet indexed in standard feeds, technical consolidation or short covering if the stock had been oversold, earnings or regulatory news released after the headline cutoff, or retail investor interest driven by social media or forums. Small-cap ADRs can be thinly traded and volatile, and low share prices near or below $3 can attract speculative positioning. Without access to the actual news or trading volume data, we cannot distinguish between fundamental and technical causes.

AEON

AEON Biopharma, Inc.Healthcare

$0.86+$0.13

+18.5%

AMEX · Mkt cap $9.9 M

No news headlines were found in the last 48 hours, so the cause of AEON's 18.49% gain cannot be directly identified from available information.

Without recent headlines, the driver of today's move remains unclear. AEON Biopharma is a small-cap biotech stock trading at $0.86, a category typically sensitive to clinical trial announcements, regulatory decisions (FDA actions), partnership news, or earnings surprises. The stock could have reacted to an announcement made outside the Yahoo Finance RSS feed, a delayed market reaction to older news, technical buying pressure, options expiration activity, or short covering. Small-cap biotechs often show volatile intraday moves on limited volume, so the move could also reflect relatively light trading rather than a fundamental catalyst. Without access to the full news universe or trading data, attributing this specific gain to a particular cause would be speculative.

CTEV

Claritev CorporationHealthcare

$16.42+$2.55

+18.4%

NYSE · Mkt cap $662 M

CTEV rose 18.39% on a day when the broader healthcare sector advanced, but no company-specific news was disclosed in the available headlines, making the exact catalyst unclear.

The provided headlines document only a general healthcare sector rally on May 18, with the NYSE Healthcare Index and State Street Healthcare benchmarks posting modest gains of around 0.4%. No news specific to Claritev Corporation itself—no earnings report, FDA decision, clinical trial result, partnership announcement, or guidance update—appears in the available sources. The stock's outsized 18.39% gain compared to the sector's fractional advance suggests either a company-specific catalyst not captured in these particular headlines, a technical rebound after prior weakness, short covering, or an announcement made outside the Yahoo Finance RSS feed window. Without additional information, the move cannot be firmly attributed to disclosed fundamental news.

OSCX

Defiance Daily Target 2X Long OSCR ETF

$89.49+$13.84

+18.3%

NASDAQ

No news headlines were found in the last 48 hours, but OSCX is a 2X leveraged long ETF tracking OSCR, so a strong rally in the underlying OSCR index likely amplified into this 18% gain through the leverage structure.

The absence of recent news headlines makes it impossible to identify a specific catalyst announcement. However, OSCX is a daily target 2X long leveraged ETF, which by design magnifies the daily returns of its underlying index OSCR by approximately two times. An underlying move of roughly 9% in OSCR would naturally produce an 18% move in OSCX before accounting for expense drag and daily rebalancing effects. The cause of the OSCR rally itself remains unknown from the provided information—it could stem from sector-specific positive developments, broad market strength, a delayed earnings or merger announcement in OSCR constituent stocks, or technical momentum. Without news on OSCR itself or visibility into its component stocks, we cannot determine the root cause, only confirm that the 2X leverage multiplier is functioning as designed.

LVO

LiveOne, Inc.Communication Services

$6.22+$0.94

+17.8%

NASDAQ · Mkt cap $52 M

LiveOne's subsidiary CPS announced expectations for $3.5M+ in revenue and $700K+ in cash flow following restructuring, with all subsidiaries projected to achieve positive Adjusted EBITDA in fiscal 2027, combined with active M&A fielding that likely sparked the 17.8% rally.

The headline establishes concrete forward guidance from a major subsidiary showing profitability milestones (positive Adjusted EBITDA across all units by FY2027) paired with near-term cash generation targets. The announcement also explicitly mentions that the company and its bankers are actively fielding M&A interest in the Celebrity Brands division. For a micro-cap stock trading around $6, positive cash flow guidance and tangible M&A activity represent material catalysts. The rebranding effort and refocus on Celebrity Brands signals operational clarity after apparent restructuring. These are not earnings beats or guaranteed outcomes, but forward-looking commitments that the market appears to have rewarded as confidence-restoring after what is likely a history of losses or uncertainty at LiveOne.

SOAR

Volato Group, Inc.Industrials

$0.16+$0.02

+17.6%

AMEX · Mkt cap $7.8 M

Volato announced a pro-forma cash balance of $5.5 million at March 31, 2026, equating to $0.14 per share, likely triggering the 17.6% gain as investors reacted positively to disclosed liquidity metrics.

On May 18, 2026, Volato Group confirmed a pro-forma cash position of $5.5 million as of March 31, 2026, with an implied per-share cash value of $0.14. This announcement appears to have been the primary catalyst for the stock's jump from prior levels to $0.16. For a micro-cap or penny stock trading at $0.16, confirmation of tangible cash backing per share can be meaningful, as it establishes a floor valuation and reduces uncertainty about balance sheet strength. The stock's current price of $0.16 exceeds the stated $0.14 cash-per-share value, suggesting investors may be assigning some value to ongoing operations or future prospects. However, the headline provides only the pro-forma figure and does not disclose material changes in business operations, partnerships, or strategic direction that might explain outsized enthusiasm beyond the cash confirmation itself.

NEPH

Nephros, Inc.Healthcare

$3.68+$0.55

+17.6%

NOWL

GraniteShares 2x Long NOW Daily ETF

$5.19+$0.77

+17.4%

NASDAQ

No news headlines were found in the last 48 hours, but NOWL is a 2x leveraged long ETF on ServiceNow (NOW), so a strong gain in NOW stock would mechanically amplify into a roughly double move in the ETF.

The absence of recent news headlines makes direct causation impossible to establish. However, NOWL is a daily leveraged ETF designed to deliver twice the daily return of ServiceNow (NOW). A 17.42% gain in NOWL would be consistent with roughly an 8-9% move in the underlying NOW stock, which could plausibly occur on positive earnings, a favorable analyst upgrade, an industry tailwind, or contract win by ServiceNow itself. Without access to ServiceNow news or market data from the snapshot date, the specific catalyst cannot be confirmed. The leverage structure explains why NOWL moved larger than a typical equity would, but does not explain what moved NOW itself.

Biggest Losers

Mon, May 18, 2026 50

BTM

Bitcoin Depot Inc.Financial Services

$0.78−$2.15

-73.2%

LICN

Lichen International LimitedIndustrials

$3.77−$3.31

-46.8%

NASDAQ · Mkt cap $21 M

No news headlines were found in the last 48 hours for LICN, so the 46.75% drop cannot be tied to any disclosed event; likely causes include a delayed earnings miss, executive announcement, reverse split, or other unannounced corporate action.

The absence of recent news headlines is notable given the severity of the move, which ranks LICN as the second biggest loser of the day. A drop of this magnitude typically correlates with a material negative catalyst, yet no information appears in the Yahoo Finance RSS feed for the past 48 hours. This could indicate that the news broke outside the tracked sources, or that the triggering event occurred before the 48-hour window but market reaction accelerated today. Possible categories of catalyst include earnings results (particularly if a miss), management departures or guidance cuts, regulatory setbacks, facility closures, or corporate restructuring announcements. For a smaller-cap company like LICN, material news can also include warrant or rights offerings, reverse stock splits, or loan covenant breaches that trigger delisting concerns. Without access to the actual news, attribution remains speculative.

GOSS

Gossamer Bio, Inc.Healthcare

$0.19−$0.15

-43.3%

NASDAQ · Mkt cap $77 M

Gossamer Bio fell 43% after reporting a Q1 loss wider than expected despite beating revenue, combined with a debt restructuring announcement that dilutes equity holders, raising concerns about runway and cash burn.

On May 18, 2026, Gossamer Bio reported first-quarter earnings that missed on the bottom line with a worse-than-expected net loss, even though revenue beat analyst forecasts. The same day, the company announced an exchange offer to eliminate over $120 million in debt with noteholder support, a signal of financial stress that typically signals shareholder dilution and reduced bargaining power. While management provided a positive update on seralutinib development with a September 2026 NDA submission target for pulmonary arterial hypertension, the combination of deteriorating profitability, wider-than-expected operating losses, and urgent debt restructuring outweighed the clinical milestone. For a clinical-stage biotech with limited cash, a larger-than-forecast quarterly burn rate raises questions about cash runway and the likelihood of further dilution before potential product approval.

WOK

WORK Medical Technology Group Ltd.Healthcare

$0.38−$0.28

-42.4%

NASDAQ · Mkt cap $5.2 M

No news headlines were found in the last 48 hours, so the 42% drop cannot be attributed to a publicly reported event; the cause remains unknown without additional context about the stock or market conditions.

The absence of any news in the Yahoo Finance RSS feed over the past two days makes it impossible to identify a specific catalyst for this severe 42% decline. WORK Medical Technology Group is a small-cap stock trading at $0.38, which typically makes it susceptible to high volatility driven by several potential factors not captured in the headlines provided. For stocks in this price range and market cap, common causes of sharp declines include delayed earnings announcements, clinical trial setbacks, regulatory actions, dilutive financing rounds, insider selling, or shifts in analyst sentiment that may not immediately appear in major news feeds. It is also possible that the decline reflects delayed market reaction to an earlier announcement or represents a technical breakdown. Without access to press releases, SEC filings, or broader market news outside the provided RSS, the specific trigger cannot be determined.

YOOV

Concorde International Group Ltd.Industrials

$0.78−$0.50

-39.1%

NASDAQ · Mkt cap $139 M

No news headlines were found in the last 48 hours for YOOV, so the 39% single-day drop cannot be attributed to a specific reported event; the cause remains unknown without access to intraday developments or market data.

The absence of recent news headlines makes it impossible to pinpoint a definitive catalyst for the severe 39% decline. For a micro-cap stock trading near $0.78, common drivers of outsized single-day moves include delayed earnings announcements or guidance revisions that may not yet be reflected in Yahoo Finance RSS feeds, technical capitulation or margin calls in low-liquidity names, unconfirmed rumors or regulatory actions announced outside major news channels, or sector-wide contagion effects. Without visibility into intraday announcements, filing updates, or real-time trading developments, any assignment of cause would be speculative. The rank as the fifth-biggest loser suggests broad selling pressure rather than stock-specific idiosyncratic news, though for such a thinly-traded security, volume and positioning changes alone can drive extreme moves.

NEOV

NeoVolta Inc.Industrials

$1.60−$0.96

-37.5%

NASDAQ · Mkt cap $214 M

No relevant headlines were found in the last 48 hours, so the 37.5% drop cannot be attributed to announced news. The decline likely stems from technical selling, a delayed market reaction, or unannounced developments affecting a small-cap microcap stock.

NeoVolta is a microcap company that manufactures home energy storage systems. The complete absence of headlines in the last 48 hours is notable given the severity of the decline, which ranks it as the sixth-biggest loser of the day. For stocks in this size category, sharp declines without concurrent news coverage often reflect technical factors such as stop-loss cascades, options-related hedging, or changes in sentiment among retail investors. Alternatively, the catalyst may have occurred outside the headline window captured by the data, or an unannounced event could have driven institutional selling. Microcap stocks are particularly prone to sharp moves on low volume and can be sensitive to broader market conditions or sector rotation.

LABT

Lakewood-Amedex Biotherapeutics Inc. Common StockHealthcare

$0.96−$0.54

-36.0%

NASDAQ · Mkt cap $3.8 M

LABT announced positive data for its lead diabetic foot ulcer candidate on the same day it fell 36%, suggesting the market viewed the results as either underwhelming relative to expectations or that other negative factors (financing, dilution, clinical setback details) overwhelmed the headline news.

The company released positive clinical data for Nu-3 in infected diabetic foot ulcers on May 18, which would typically support a stock price. However, LABT dropped 36% that same day, ranking among the market's largest losers. This disconnect between a positive announcement and severe selling pressure suggests either the data disappointed versus investor expectations (efficacy, safety, or trial design concerns), the market focused on unfavorable details buried in the full release, or a separate catalyst (financing dilution, insider selling, broader sector weakness, or pipeline setback) drove the move independent of the headline announcement. Without access to the full press release text, analyst commentary, or market context, the precise reason for the sharp decline remains unclear. The magnitude of the loss and timing on announcement day implies the market's reaction directly tied to how it interpreted the Nu-3 data or accompanying developments, not general biotech sector volatility.

BNZI

Banzai International, Inc.Technology

$5.08−$2.58

-33.7%

NASDAQ · Mkt cap $5.6 M

No news headlines were available in the last 48 hours, so the 33.68% drop cannot be attributed to a disclosed catalyst; the cause likely involves technical selling, sector rotation, or undisclosed company news.

Banzai International experienced a severe single-day decline ranking it the eighth-biggest loser on NASDAQ, yet zero news items appeared in the Yahoo Finance RSS feed over the preceding two days. This disconnect between magnitude of move and absence of public disclosure suggests either a technical or algorithmic trigger unrelated to fundamental news, a delayed market reaction to older information, or a potential company announcement that has not yet propagated through major financial news channels. Without knowing Banzai's market capitalization, liquidity profile, or sector, the most likely hypotheses are broad market or sector weakness, institutional rebalancing, short covering reversal, or an unannounced earnings miss or guidance cut that may surface in coming hours. The stock closed at $5.08, indicating it remains micro or small-cap where price volatility and news lag times are often higher than large-cap equivalents.

TDIC

Dreamland Limited Class A Ordinary SharesCommunication Services

$0.71−$0.34

-32.3%

NASDAQ · Mkt cap $4.0 M

No news headlines were published in the last 48 hours, so the 32% drop cannot be attributed to a specific disclosed event. The cause likely falls into technical selling, market-wide pressure, or undisclosed company-specific developments.

Despite TDIC being ranked the ninth biggest loser on the day with a sharp 32% decline, Yahoo Finance has returned no headlines from the prior 48 hours to explain the move. This absence of disclosed news makes causal inference difficult. For a micro-cap or thinly traded stock like Dreamland Limited, large single-day drops often reflect technical selling, thin liquidity amplifying price moves, or delayed reporting of company announcements that may not yet have reached major news aggregators. Alternatively, the decline could stem from social media rumors, insider activity, or broader market selloff in a specific sector. Without access to press releases, regulatory filings, or trading volume data, identifying the specific catalyst is not possible from the information provided.

CPHI

China Pharma Holdings, Inc.Healthcare

$0.71−$0.33

-31.7%

AMEX · Mkt cap $44 M

No news headlines were reported in the last 48 hours, so the 31.72% drop cannot be directly attributed to a disclosed event. The decline likely reflects selling pressure from a specific catalyst unrelated to publicly announced information.

CPHI experienced a severe single-day loss of nearly 32% with no corresponding news items appearing in the available 48-hour window. This absence of disclosure does not rule out a cause, but rather suggests the catalyst may be undisclosed, delayed in publication, or reflective of trader behavior not tied to hard news. For a micro-cap stock like CPHI trading at $0.71, typical drivers of sharp declines include: changes in capital structure or dilution announcements, regulatory actions not yet widely reported, insider selling signals, short-seller reports, loss of institutional support, or technical breakdown from accumulated selling pressure. Without access to the company's official disclosure channels or real-time trader communication, the specific trigger remains opaque.

EDSA

Edesa Biotech, Inc.Healthcare

$9.00−$4.05

-31.0%

NASDAQ · Mkt cap $55 M

No news headlines were available in the last 48 hours to explain EDSA's sharp 31% drop on May 18, 2026. The catalyst remains unknown based on publicly reported information.

The absence of any Yahoo Finance headlines in the last 48 hours means we cannot pinpoint a specific catalyst for this significant decline. Edesa Biotech is a small-cap biotech company, and stocks in this sector are typically sensitive to clinical trial data releases, FDA decisions, funding announcements, or pipeline updates. Given the magnitude of the drop ranking it as the 11th biggest loser of the day, the cause was likely material news. Possibilities include negative clinical trial results, an unexpected FDA rejection, dilutive financing news, executive departures, or a significant patent setback, but these are speculative. It is also possible the news broke outside the monitored RSS feed window or through channels not captured by Yahoo Finance's standard coverage.

MRNO

Murano Global Investments PLC Ordinary SharesReal Estate

$0.40−$0.17

-30.3%

NASDAQ · Mkt cap $19 M

A 30% drop in MRNO with no concrete news tied directly to the stock suggests either a broad market reaction to Trump's comments on financial concerns or an unrelated company-specific event not captured in the available headlines.

The single headline references Trump's controversial remark about not thinking about Americans' financial situation and notes that micro-cap stocks in forgotten corners of the market reacted, but the article explicitly mentions these were "unlikely winners," not losers. MRNO is down sharply, which does not align with the winner narrative in that headline. No earnings release, guidance cut, regulatory action, or company-specific news appears in the provided sources. The move could stem from a delayed negative announcement, a technical breakdown in a thinly traded micro-cap, sector rotation, or short covering that wasn't captured in the Yahoo Finance RSS feed. For a stock at $0.40 trading on NASDAQ, liquidity is typically thin, making price moves susceptible to outsized reactions to minor catalysts or lack thereof.

RENX

RenX Enterprises Corp.Real Estate

$1.50−$0.58

-27.7%

NASDAQ · Mkt cap $5.2 M

RENX plunged 27.71% with no news headlines in the last 48 hours, so the specific catalyst is unknown; the move may reflect technical selling, unannounced company developments, or broader market factors affecting micro-cap stocks.

No news headlines were found in the last 48 hours to explain RENX's steep 27.71% decline, which ranks it among the day's thirteen biggest losers. Without a reported earnings miss, guidance cut, regulatory action, or other identifiable event, the cause remains speculative. For a NASDAQ-listed micro-cap trading at $1.50, possible drivers include technical factors such as stop-loss cascades or short covering reversals, an unannounced insider development not yet picked up by major news feeds, delayed disclosure of a material event, or participation in a sector-wide selloff. Another possibility is a pre-market or after-hours announcement that has not yet propagated through standard financial news channels. The absence of any headline makes it impossible to point to a specific corporate action as the trigger.

CMND

Clearmind Medicine Inc.Healthcare

$0.38−$0.14

-26.9%

NASDAQ · Mkt cap $2.8 M

Clearmind announced a positive preclinical research agreement to study MEAI with tirzepatide on May 18, yet the stock fell 26.9% the same day, suggesting the market viewed the news as insufficient or disappointing relative to expectations or broader sector headwinds.

The company issued two press releases on May 18 announcing a research agreement to evaluate MEAI in combination with tirzepatide, a blockbuster GLP-1 obesity therapy. On its surface, this appears to be positive news establishing strategic positioning in the obesity treatment space. However, the stock dropped sharply on the announcement day, which typically indicates either (1) the market had priced in more ambitious news and found this preclinical-stage agreement insufficiently catalytic, (2) the announcement revealed execution or valuation concerns not apparent in the headlines, or (3) broader biotech sector weakness or short-covering in a low-liquidity microcap overshadowed the fundamental development. Without access to the full press release details, investor guidance, or real-time trading context, the exact disconnect between the news tone and price action cannot be definitively established from the headlines alone.

ANY

Sphere 3D Corp.Financial Services

$1.68−$0.61

-26.6%

NASDAQ · Mkt cap $17 M

No news headlines were found in the last 48 hours, so the 26.64% drop cannot be directly attributed to a reported event. The decline likely reflects either a delayed market reaction to previous news, technical selling pressure, or sector-wide weakness in the technology or infrastructure space whe…

The absence of recent headlines makes it impossible to pinpoint a specific catalyst for the sharp 26.64% drop. Sphere 3D is a small-cap technology company focused on infrastructure and edge computing solutions. Stocks in this category can be sensitive to several driver categories: shifts in market sentiment toward cloud or infrastructure spending, changes in customer demand or contract delays, insider trading activity or guidance surprises disclosed through filings rather than press releases, technical breakdown in a stock already trading at a low price point, or broader sector rotation out of smaller technology names. Without access to SEC filings, earnings reports, or corporate statements released in the exact timeframe, any specific explanation remains speculative. The drop is large enough and the stock is ranked 15th biggest loser, suggesting this was a material move tied to something substantive rather than random noise.

EDBL

Edible Garden AG IncorporatedConsumer Defensive

$0.29−$0.10

-26.3%

NASDAQ · Mkt cap $1.8 M

No news headlines were published in the last 48 hours covering EDBL, so the 26% intraday drop cannot be directly attributed to a reported event. The decline likely reflects either technical selling pressure, a delayed announcement, or market-specific factors tied to the microcap agriculture techn…

The absence of any recent news coverage is striking for a stock that ranks as the 16th biggest loser on the day. EDBL is a small-cap agricultural technology company, and such stocks can experience sharp moves on thin volume from technical factors, short covering reversals, or delayed disclosures that reach the market before formal press releases. Another possibility is that negative news was released through channels not indexed by Yahoo Finance RSS feeds within the observation window, or that an earnings report or guidance revision drove selling that has not yet been formally announced. Microcaps in the agriculture and indoor farming space have also been cyclically sensitive to commodity prices, funding availability, and regulatory sentiment. Without a headline anchor, the most honest assessment is that the cause remains unclear from the evidence provided.

GCTK

GlucoTrack, Inc.Healthcare

$0.48−$0.17

-25.7%

NASDAQ · Mkt cap $3.7 M

No news headlines were reported in the last 48 hours, so the 25.69% drop cannot be attributed to a specific announced event. The decline likely reflects either delayed market reaction to an earlier announcement, technical selling, or broad biotech sector weakness.

The absence of recent news headlines makes it impossible to identify a concrete catalyst for this sharp single-day decline. GlucoTrack is a small-cap healthcare/medical device company, and stocks in this category are particularly sensitive to several factors: clinical trial results or safety concerns that may not yet have widespread press coverage, changes in reimbursement or regulatory status, insider selling or lock-up expirations, analyst downgrades, or sector-wide pressure on biotech valuations. The stock's rank as the 17th biggest loser suggests this was a material market-wide move, which could indicate a sector-specific event affecting multiple diabetes or diagnostic device companies. Without access to the news that may have driven this decline, we cannot distinguish between these possibilities based on the available evidence.

STFS

Star Fashion Culture Holdings LimitedCommunication Services

$8.00−$2.75

-25.6%

NASDAQ · Mkt cap $5.3 M

No news headlines were found in the last 48 hours for STFS, so the 25.58% single-day drop cannot be attributed to a specific announced event. The cause likely falls into broad categories such as technical selling, sector headwinds, or untracked announcements.

Star Fashion Culture Holdings experienced a steep one-day decline with no corresponding headline coverage in the available news feeds. This absence of explanatory news makes causation difficult to establish. For a smaller-cap apparel or fashion-related stock, such drops can stem from several sources: technical or algorithmic selling following a breakdown of key price levels, broad sector weakness in retail or consumer discretionary stocks, a privately disclosed earnings miss or guidance cut that has not yet been widely reported, insider selling activity, or deteriorating market conditions for Chinese-listed equities (given the company name). Without concrete news, we cannot narrow the cause further, though the magnitude of decline suggests either fundamental deterioration or technical cascade rather than routine market noise.

DSGN

Design Therapeutics, Inc.Healthcare

$10.70−$3.67

-25.5%

NASDAQ · Mkt cap $939 M

Design Therapeutics released positive clinical trial data for its Friedreich ataxia candidate early Monday, driving the stock up 27%, but selling pressure later in the day erased all gains, likely due to profit-taking, lower-than-expected trial details, or investor skepticism about near-term comm…

The company announced four-week intravenous data from the RESTORE-FA trial of DT-216P2 showing dose-dependent clinical improvements and biomarker activity in Friedreich ataxia, which is a serious degenerative genetic disease. The stock initially surged 27% on this positive clinical update. However, the stock surrendered all gains by close, finishing down 25.54%. This intraday reversal suggests initial enthusiasm gave way to skepticism or disappointment upon deeper review of the data. Possible explanations include: (a) investors realizing the trial was only four weeks long and conducted intravenously, raising questions about longer-term durability and oral formulation viability; (b) profit-taking after the 27% spike; (c) the data being less compelling than the headlines initially suggested; or (d) recognition that rare disease drugs face significant commercial challenges despite clinical efficacy. Jim Cramer's prior comment labeling the stock "pure spec" may have also resurfaced in investor conversations during the sell-off.

SUNE

SUNation Energy Inc.Technology

$1.23−$0.42

-25.5%

NASDAQ · Mkt cap $9.2 M

SUNE plunged 25.45% on May 18, but the only available headline from May 17 discusses financing support and upside potential, offering no clear negative catalyst for the sharp selloff.

The headline released on May 17 actually contains positive language—it mentions SUNE securing financing support and being ranked among the 11 most promising renewable energy stocks with 42.5% upside potential. This is not bearish news. The headline is also truncated mid-sentence, so the full context is unknown. Given the extreme 25.45% single-day drop, several scenarios are plausible: (1) a major negative announcement or earnings miss occurred after the May 17 headline and simply was not captured in the news feed provided, (2) a market-wide sector rotation out of renewable energy stocks drove indiscriminate selling, or (3) company-specific operational or financial deterioration was revealed. Without a documented negative catalyst in the headlines supplied, the true cause remains opaque.

CURR

Currenc Group, Inc.Financial Services

$2.69−$0.90

-25.1%

NBRGR

Newbridge Acquisition Limited Rights 2026-21.10.27 For Shares

$0.15−$0.05

-25.0%

NASDAQ

No news headlines were found in the last 48 hours, so the 25% drop cannot be attributed to a specific announced catalyst. Rights offerings typically decline as expiration approaches or if the underlying acquisition faces uncertainty.

NBRGR is a SPAC rights offering with a fixed expiration date of October 27, 2026. No recent news headlines were available to explain the sharp 25% decline on May 18, 2026. For this type of security, price declines are most commonly driven by: (1) time decay as the expiration date approaches, reducing the value of the right to purchase shares; (2) deterioration in the underlying acquisition's prospects or delays in deal closure; (3) a decline in the price of the underlying Newbridge shares, which reduces the value of exercising the right; or (4) broader market weakness in SPAC-related securities. Without headline confirmation, the specific trigger is unknown, but structural factors inherent to expiring rights offerings make time decay and deal uncertainty the most plausible categories.

CTXR

Citius Pharmaceuticals, Inc.Healthcare

$0.53−$0.17

-24.8%

NASDAQ · Mkt cap $18 M

No news headlines were published in the last 48 hours, so the 24.76% drop cannot be directly attributed to a disclosed catalyst. For a small-cap biotech like Citius, the decline likely reflects a clinical setback, regulatory disappointment, or broader sector rotation, but the specific cause is un…

The absence of any news in the last 48 hours makes it impossible to pinpoint what drove the sharp decline. Citius Pharmaceuticals is a small-cap biotech company, and such stocks are typically sensitive to clinical trial results, FDA decisions, funding announcements, and pipeline updates. A 24.76% single-day drop of this magnitude in a biotech usually correlates with material negative news such as failed trial data, a denied or delayed regulatory submission, clinical hold, or significant insider selling. It is also possible that news circulated through channels not captured by Yahoo Finance's RSS feed, or that a press release was issued but not yet indexed. Without access to the company's investor relations page or SEC filings from the past 48 hours, the precise cause remains speculative.

YYAI

AiRWA Inc.Technology

$11.39−$3.59

-24.0%

ORIS

ORIENTAL RISE HOLDINGS LtdConsumer Defensive

$0.41−$0.13

-23.6%

NASDAQ · Mkt cap $545 K

No news headlines were found in the last 48 hours for ORIS, so the 23.6% drop likely stems from technical selling, a delayed announcement, or sector-wide pressure rather than a specific identifiable catalyst.

The absence of recent news headlines in this timeframe makes it impossible to pin the decline to a concrete event such as earnings, a financing announcement, regulatory action, or guidance revision. ORIS is a microcap security trading at $0.41, a price tier where stocks are often thinly traded and prone to sharp moves on low volume, thin liquidity, or momentum-driven reversals. The decline could reflect accumulated negative sentiment from an earlier announcement not yet indexed in the news feed, sector rotation, or a technical breakdown from a prior support level. Without headline evidence, we cannot distinguish between genuine company news, broader market conditions, or opportunistic short or liquidation pressure in a low-liquidity security.

TRT

Trio-Tech InternationalTechnology

$15.32−$4.73

-23.6%

AMEX · Mkt cap $114 M

TRT dropped 23.59% on 2026-05-18, but the single available headline references Trump's market-moving remarks and mentions micro-cap stocks as "unlikely winners"—a framing that suggests TRT may not have been among those winners, though no specific reason for TRT's decline is stated.

The provided headline does not identify a specific catalyst for TRT's decline. The article discusses Trump's comments rattling markets and notes that certain forgotten stocks under $30 were unlikely winners, but TRT is not explicitly named as either a winner or loser, nor is any company-specific news provided. Given that TRT is a micro-cap trading under $30 on AMEX, it is plausible the stock was caught in broader market turbulence from Trump's remarks, but this remains inference. Alternatively, the timing could be coincidental and the real driver could be earnings disappointment, guidance cut, operational setback, or sector-specific headwinds affecting semiconductor or electronics testing companies like Trio-Tech. Without concrete company news, the cause remains unconfirmed.

IPST

IP Strategy Holdings, Inc.Consumer Defensive

$7.48−$2.21

-22.8%

HIMZ

Daily Target 2X Long HIMS ETF

$22.44−$6.32

-22.0%

NASDAQ

No news headlines were found in the last 48 hours to explain the sharp 21.98% drop in HIMZ, but the move likely reflects a sharp decline in the underlying Hims & Co stock or broader healthcare weakness.

HIMZ is a 2X leveraged long ETF tracking Hims & Co, a digital health and telehealth company. With no news identified in the headline feed, the decline cannot be attributed to a specific company announcement, FDA action, earnings miss, or guidance cut. However, the sharp 22% drop is consistent with what a 2X leveraged product would show if its underlying stock fell roughly 11% on significant volume. The underlying decline could stem from several common triggers in the telehealth sector: weaker-than-expected patient growth, margin pressure, competitive pressure from incumbents, insurance coverage changes, reimbursement rate cuts, or broader healthcare stock sell-off. Without access to real-time data or news beyond the 48-hour window provided, the specific catalyst remains unconfirmed. The absence of headlines does not rule out after-hours news, earnings announcements on adjacent dates, or significant intraday developments that did not appear in this feed.

PMAX

Powell Max Limited Class A Ordinary SharesFinancial Services

$2.50−$0.69

-21.6%

NASDAQ · Mkt cap $2.1 M

No news headlines were found in the last 48 hours for PMAX, so the 21.63% drop cannot be directly attributed to a specific announced event; the cause likely involves technical selling, market-wide pressure, or unannounced company developments.

Yahoo Finance returned no headlines for Powell Max Limited in the past 48 hours despite a significant single-day loss ranking it as the 29th biggest loser on NASDAQ. This absence of news is notable and suggests the decline was not triggered by a major publicized corporate announcement, earnings report, regulatory action, or guidance change. For a small-cap or micro-cap equity like PMAX, possible explanations include technical selling or chart-based liquidations, broad market sector weakness affecting similar companies, insider trading activity or delayed disclosure filings, or rumors circulating on social media or trading forums that have not yet reached mainstream financial news outlets. Without access to real-time order flow, options activity, or insider transaction data, attributing the move to any single catalyst is speculative.

BOT

RoboStrategy, Inc. Common StockFinancial Services

$28.36−$7.65

-21.2%

NASDAQ · Mkt cap $665 M

No news headlines were available in the last 48 hours, so the 21% drop cannot be directly attributed to a specific announced event. The move likely reflects either delayed market reaction to unreported news, technical selling, or sector-wide pressure affecting robotics or automation stocks.

The absence of any news headlines in the 48-hour window before this significant 21% decline makes direct attribution impossible. RoboStrategy appears to be a robotics or automation-focused company based on its name, but without recent headlines or earnings reports, guidance changes, regulatory actions, or partnership announcements to anchor the analysis, we must rely on inference. Stocks in the automation and robotics space can be sensitive to broader economic sentiment shifts, interest rate expectations, or supply chain concerns that may not always generate immediate press coverage. Alternatively, the stock could have reacted to news that simply was not picked up by the Yahoo Finance RSS feed within the snapshot window, or the decline may reflect technical factors such as options expiration, index rebalancing, or short-covering rather than fundamental developments.

TBH

Brag House Holdings, Inc.Technology

$0.65−$0.17

-20.7%

NASDAQ · Mkt cap $4.8 M

No news headlines appeared in the last 48 hours to explain the 20.73% drop in TBH stock, so the decline likely resulted from technical selling, market-wide weakness, or undisclosed company developments.

The absence of any Yahoo Finance headlines in the 48-hour window around this significant single-day decline leaves the direct cause unclear. Brag House Holdings is a micro-cap NASDAQ stock trading at $0.65, and stocks in this category are prone to sharp moves on relatively low volume without broad media coverage. Possible explanations include routine technical liquidation or profit-taking if the stock had rallied recently, sector-wide pressure affecting micro-caps or a specific industry segment, or a company announcement that did not yet appear in the RSS feed or mainstream financial press. Without material news in the record, it is also possible the company issued guidance, disclosed an insider transaction, or faced operational news that simply did not trigger major headlines yet. The 20.73% magnitude suggests more than random volatility, but without headlines or structural context about TBH's business, leverage, or short-float dynamics, a confident root cause cannot be identified from available evidence.

ARTL

Artelo Biosciences, Inc.Healthcare

$1.46−$0.38

-20.7%

NASDAQ · Mkt cap $3.3 M

No news headlines were found in the last 48 hours, so the 20.65% drop likely stems from a delayed announcement, technical selling, or market-specific event not yet captured in public headlines.

Artelo Biosciences is a small-cap biotech company with limited liquidity and high price volatility. The absence of any news in the past 48 hours does not rule out a significant catalyst; biotech stocks often react sharply to clinical trial results, regulatory decisions, funding announcements, or changes in management. Given the size and stage of the company, the drop could reflect delayed disclosure of adverse trial data, a failed FDA milestone, a dilutive financing round, insider selling, or simply momentum-driven technical selling in a down market. Without access to company filings, press releases beyond the news feed, or real-time market data showing block trades or insider transactions, the specific trigger remains unclear.

MWC

Micware Co., Ltd. American Depositary SharesConsumer Cyclical

$6.35−$1.65

-20.6%

NASDAQ · Mkt cap $88 M

No news headlines were published in the last 48 hours for MWC, so the 20.63% drop cannot be attributed to a specific announced event; the decline likely reflects either a delayed market reaction to untracked news, technical selling, or a sector-wide downturn.

The absence of any Yahoo Finance headlines in the 48-hour window surrounding this sharp 20.63% drop makes it impossible to pinpoint a definitive catalyst from the available evidence. MWC experienced a substantial single-day loss ranking it the 33rd biggest loser on NASDAQ, yet no recent earnings report, guidance change, regulatory action, or corporate announcement appears in the news feed provided. This gap suggests either that the catalyst is not yet widely covered by mainstream news outlets, the drop was driven by technical factors such as stop-loss accumulation or short covering reversals, or the stock reacted with a lag to older news not captured in this 48-hour snapshot. For a smaller-cap stock like this, sector rotation, liquidity concerns, or changes in institutional positioning could also explain sharp single-day moves without accompanying news.

AKAN

Akanda Corp.Healthcare

$16.30−$4.18

-20.4%

NASDAQ · Mkt cap $2.6 M

No news headlines were published in the last 48 hours for Akan Corp., so the 20.41% drop cannot be directly attributed to a specific announced event. The decline likely reflects either technical selling, delayed reaction to prior news, or market sentiment shift in the cannabis sector.

The absence of recent headlines creates a genuine challenge in pinpointing the cause of this sharp one-day decline. Akanda Corp. operates in the cannabis industry, a sector historically prone to rapid repricing on sentiment shifts, regulatory developments, or shifts in institutional positioning. Without identifiable breaking news, three plausible categories emerge: first, a delayed market reaction to older company developments or sector-wide headwinds not yet surfaced in the news feed; second, technical selling around a resistance level or broader cannabis stock weakness unrelated to company-specific events; third, an announcement made through channels not captured in the Yahoo Finance RSS feed (conference call, SEC filing, investor relations update). The 20.41% magnitude suggests material rather than routine selling pressure.

BGM

BGM Group Ltd.Healthcare

$0.28−$0.07

-20.1%

NASDAQ · Mkt cap $112 M

BGM Group fell 20% on May 18 with no news headlines identified in the last 48 hours, making the specific catalyst unclear; the drop likely reflects either a delayed market reaction to untracked news, technical selling, or sector-wide pressure.

No recent headlines were found in the Yahoo Finance RSS feed for the past 48 hours surrounding BGM's sharp 20% decline, which limits our ability to pinpoint a specific catalyst. For a low-priced NASDAQ stock trading at $0.28, common drivers of sudden drops typically include disappointing earnings or guidance revisions, dilutive financing announcements, regulatory setbacks, executive departures, or adverse developments at key business segments. It is also possible the stock declined on Friday May 17 in response to news published earlier in the week that was not recaptured in the 48-hour window, or that the move reflects technical liquidation or sector rotation. Without access to company filings, press releases, or earlier news coverage, we cannot distinguish among these hypotheses with confidence.

AGPU

Axe Compute Inc.Technology

$4.68−$1.17

-20.0%

NASDAQ · Mkt cap $23 M

No headlines are available for AGPU in the last 48 hours, so the 20% drop cannot be attributed to a specific disclosed event; the decline likely reflects either broad sector weakness, technical selling, or undisclosed company developments.

The absence of any news headlines in Yahoo Finance's recent feeds over the past 48 hours makes it impossible to pinpoint a definitive catalyst for the 20% intraday drop. This is a substantial single-day loss that typically signals either a material company announcement not yet captured in headline feeds, sector-wide pressure affecting compute-related stocks, or technical/algorithmic selling. AGPU's modest stock price of $4.68 and ranking as the 36th largest loser suggests it may be a smaller-cap or lower-priced equity more susceptible to volatility swings. Possible categories of cause include earnings or guidance disappointment released after market close yesterday, executive departure, contract loss, regulatory issue, or simply sharp profit-taking if the stock had gained prior. Without corroborating headlines, all explanations remain speculative.

USBC

USBC, Inc.Technology

$0.44−$0.11

-19.5%

AMEX · Mkt cap $162 M

No news headlines were found in the last 48 hours to explain USBC's 19.51% drop, so the cause remains unknown without additional information about company announcements, market conditions, or trading activity.

The absence of recent news makes it difficult to pinpoint a specific catalyst for the decline. USBC trades on the AMEX with a very low share price of $0.44, which is characteristic of a penny stock or distressed security. Stocks in this category can experience large percentage swings on minimal volume, technical chart breaks, short liquidations, or delayed news dissemination that may not immediately appear in RSS feeds. The move could reflect a delayed market reaction to an announcement made just outside the 48-hour window, deteriorating fundamentals revealed in a recent filing, a delisting warning, or simply thin liquidity amplifying normal trading activity. Without access to company filings, insider transactions, or trading volume data, attributing the drop to a specific event would be speculation. Broader market weakness or sector rotation are also possibilities, though these would typically not produce a move this severe in isolation.

PIII

P3 Health Partners Inc.Healthcare

$9.17−$2.12

-18.7%

NASDAQ · Mkt cap $1.8 B

No news directly tied to PIII's 18.74% decline was provided; the stock may have been caught in broader market volatility following Trump's controversial remarks, though the connection is speculative.

The only headline mentioning PIII context references Trump's market-moving comments and notes that "forgotten stocks under $30" showed unexpected moves, but it does not specify whether PIII was a winner or loser in that reaction, nor does it explain the mechanism. PIII is a healthcare provider company, and a micro-cap name like this typically responds to factors such as earnings surprises, Medicare/Medicaid reimbursement changes, operational guidance revisions, provider credentialing issues, or broader healthcare sector sentiment shifts. The absence of concrete news tied to PIII itself means the sell-off could reflect sector rotation out of healthcare names, general risk-off positioning, or a company-specific event not captured in the RSS feed provided. Without additional detail, attributing this move to Trump's remarks is reasonable only as a very loose market-mood hypothesis.

GENB

Generate Biomedicines, Inc.Healthcare

$13.01−$3.00

-18.7%

NASDAQ · Mkt cap $2.1 B

No news headlines were found in the last 48 hours to explain Generate Biomedicines' 18.72% drop, so the cause remains unknown without additional context on company announcements, clinical trial results, or market-wide biotech selloffs.

The absence of recent news headlines makes it difficult to pinpoint a specific catalyst for this substantial single-day decline. Generate Biomedicines is a clinical-stage biotech firm focused on protein design, a sector known for high volatility driven by trial outcomes, regulatory decisions, and funding events. The 18.72% drop could reflect a delayed announcement that has not yet surfaced in the RSS feed monitored, a negative development disclosed after market hours on May 17th, a broad sector rotation away from biotech, or reaction to competitive or clinical setbacks. Without access to the company's press releases, SEC filings, or social media announcements from the snapshot date, it is not possible to isolate a concrete cause. The magnitude of the move suggests a material event rather than algorithmic or technical trading alone.

AIIR

Air Global PLC Ordinary SharesConsumer Defensive

$10.44−$2.39

-18.6%

NASDAQ · Mkt cap $1.2 B

No news headlines were found in the last 48 hours for AIIR, making it impossible to identify a specific catalyst for the 18.63% decline. The drop likely reflects market sentiment shift, technical selling, or delayed news not yet captured by the feed.

The absence of any recent headlines in Yahoo Finance's RSS feed over the past two days means we cannot point to an earnings miss, regulatory action, guidance cut, acquisition news, or other company-specific event as the cause of AIIR's significant 18.63% drop. For a stock declining this sharply without visible news coverage, typical causes include technical selling triggered by chart breaks or support loss, broad sector rotation out of the stock's category, delayed earnings or financial statement disclosures not yet indexed by the news aggregator, or unverified market rumors circulating on social media or alternative platforms. Without access to intraday trading data, insider filings, or real-time news feeds beyond Yahoo Finance, we cannot distinguish between these scenarios. The stock's position as the 40th biggest loser suggests its decline was meaningful but not among the day's most extreme moves.

SMX

SMX (Security Matters) Public Limited CompanyIndustrials

$6.67−$1.52

-18.6%

NASDAQ · Mkt cap $17 M

SMX fell 18.56% on minimal news; the only available headline is a generic press release about recycling and plastic economics with no earnings, guidance, or material announcement that would clearly justify a sharp selloff.

The provided headline from May 17 is a general corporate statement about certified recycling and plastic infrastructure—a sustainability-focused topic with no mention of earnings misses, guidance cuts, product recalls, regulatory setbacks, or operational disruptions. The timing and content of this press release do not establish an obvious catalyst for an 18.56% single-day decline. Possible explanations consistent with this lack of negative news include: (a) a delayed market reaction to prior negative news not captured in the 48-hour window, (b) sector-wide selling pressure in recycling or materials stocks, (c) a technical or short-covering event unrelated to fundamentals, or (d) breaking news outside this RSS feed (earnings-related or otherwise). Without additional context on SMX's recent operational performance, guidance, or competitive position, the true driver remains unclear.

NBIL

GraniteShares 2x Long NBIS Daily ETF

$33.70−$7.55

-18.3%

NASDAQ

No headlines were reported in the last 48 hours, but NBIL is a 2x leveraged ETF tracking the Nasdaq-100 short inverse index, so a sharp intraday decline most likely reflects a significant rally in the Nasdaq-100 itself, which moves this fund inversely and with double the magnitude.

NBIL is a daily inverse leveraged ETF designed to move -2x the daily return of the Nasdaq-100. With no news headlines provided, the 18.3% single-day drop cannot be attributed to company-specific or sector-specific announcements. Instead, the most probable cause is a sharp rally in the underlying Nasdaq-100 index. A roughly 9% gain in the Nasdaq-100 would produce approximately this magnitude of loss for a -2x inverse product. This type of move is structural and mechanical rather than news-driven. Inverse leveraged ETFs are particularly sensitive to daily volatility and rebalancing, and major index rallies—whether driven by Fed policy shifts, economic data, or broad risk-on sentiment—are the typical catalyst for losses in these instruments. Without specific market data provided, we cannot pinpoint the exact nature of the Nasdaq's move, but that remains the most logical explanation for this fund's performance.

ONCO

Onconetix, Inc.Healthcare

$0.31−$0.07

-18.3%

NASDAQ · Mkt cap $2.8 M

No news headlines were found in the last 48 hours to explain Onconetix's 18% decline, so the drop likely stems from broad market conditions, technical selling, a delayed announcement not yet widely reported, or sector headwinds in biotech.

Onconetix is a micro-cap trading at $0.31 with an 18% single-day loss and no recent news coverage available. For stocks at this price level and market-cap tier, moves of this magnitude often occur without synchronized media coverage. Possible drivers include: one, a private development or clinical setback disclosed directly to shareholders or the market but not yet picked up by major news feeds; two, technical or algorithmic selling triggered by a support break or stop-loss cascade; or three, broader biotech sector weakness that disproportionately affects smaller-cap names. Without access to SEC filings, press releases, or message boards from the snapshot date, we cannot identify a specific catalyst. The absence of any headline is itself notable given the stock's ranking as the 43rd biggest loser on the day.

DXF

Eason Technology LimitedFinancial Services

$1.14−$0.25

-18.0%

AMEX · Mkt cap $1.6 M

DXF fell 18% on Monday amid a broad decline in Asian equities traded as American Depositary Receipts, with no company-specific news to explain the outsized move relative to the sector.

The only headline provided is a generic statement that Asian equities trading as ADRs declined on Monday morning, with no mention of Eason Technology specifically or any catalyst tied to the company. The decline appears to be part of a broader sector weakness affecting Asian ADRs. However, DXF's 18% drop significantly outpaces the vague description of the ADR sector decline, suggesting either the ADR index fell sharply enough to warrant such a loss or there is company-specific negative news not captured in the provided headlines. Without earnings results, guidance changes, regulatory actions, or other identifiable catalysts, the precise driver remains unclear. The most likely categories are either a sharp market-wide repricing of Asian equities or undisclosed company-specific developments.

NBIG

Leverage Shares 2x Long NBIS Daily ETF

$23.62−$5.12

-17.8%

NASDAQ

No news headlines were found in the last 48 hours. NBIG is a 2x leveraged long ETF tracking NBIS, so a ~9% drop in the underlying index would mechanically produce this 17.81% decline through leverage amplification.

The absence of any news in the past 48 hours means we cannot identify a specific catalyst for the move based on published information. However, NBIG is a structured product that delivers 2x daily leveraged exposure to NBIS, meaning its price movements are fundamentally driven by the performance of its underlying index. A decline of approximately 8.9% in NBIS would mechanically result in a roughly 17.8% loss in NBIG due to the leverage multiplier. The move itself is therefore consistent with a sharp underlying index decline, which could stem from various sources including broad market sell-offs, sector-specific weakness, shifts in macroeconomic expectations, or overnight international developments. Without news or market context provided, the most likely category of cause is a broad market or sector rotation affecting the underlying NBIS index.

ONFO

Onfolio Holdings, Inc.Communication Services

$0.72−$0.16

-17.8%

NASDAQ · Mkt cap $334 K

Onfolio fell 17.76% despite announcing four acquisitions expected to add $4.1M in EBITDA, likely because Q1 2026 revenue dropped sharply year-over-year, disappointing the market and outweighing the forward-looking acquisition news.

The stock faced conflicting signals on May 18. Management announced exclusive Letters of Intent for four acquisitions projected to double revenue run rate and achieve positive free cash flow, which would normally be bullish. However, the company simultaneously reported Q1 2026 results showing a sharp year-over-year decline in quarterly revenue, despite efficiency improvements. The premarket decline of over 6% on the earnings miss appears to have accelerated into a much steeper close, suggesting the market weighted the negative current-quarter result more heavily than the aspirational acquisition pipeline. The acquisitions are contingent on completion and offer only projected future value, whereas the revenue decline is concrete and immediate, likely driving the disconnect between the positive deal announcement and the 17.76% sell-off.

RXT

Rackspace Technology, Inc.Technology

$4.80−$1.02

-17.5%

NASDAQ · Mkt cap $839 M

No news headlines were found in the last 48 hours for Rackspace Technology, so the 17.53% drop cannot be directly attributed to a named catalyst. The decline likely reflects broad sector weakness, technical selling, or undisclosed market developments.

The absence of recent news headlines makes it difficult to pinpoint a specific cause for RXT's steep single-day decline. Rackspace is a managed cloud services and hosting provider, and IT services stocks can be sensitive to broad technology sector rotations, macroeconomic data releases, interest rate expectations, or changes in cloud spending trends. Without access to intraday trading activity or earnings announcements, analyst downgrades, or competitive announcements, the most probable explanations fall into general categories: sector-wide selloff in cloud or IT services, technical breakdown of a support level, short covering that reversed, or an undisclosed company-specific event that had not yet been reported to Yahoo Finance RSS by the snapshot date. Given the magnitude of the move and the absence of headline support, this appears more likely to reflect broad market or sector dynamics rather than company-specific news.

LZMH

LZ Technology Holdings Limited Class B Ordinary SharesTechnology

$0.08−$0.02

-17.5%

NASDAQ · Mkt cap $11 M

No news headlines were available in the past 48 hours to explain LZMH's 17.51% drop, so the cause remains unclear without additional context.

Yahoo Finance returned no headlines for LZMH in the last 48 hours, making it impossible to attribute the decline to a specific corporate event such as earnings, guidance, regulatory action, or M&A. LZMH is a thinly-traded, low-priced microcap stock trading at $0.08, a profile typical of companies with limited analyst coverage and high sensitivity to technical selling, institutional delisting risk, or secondary market dynamics. Possible categories of catalyst include margin-call forced liquidation by holders, negative social media chatter, sector rotation out of small-cap tech, or a delayed news item not yet indexed by the RSS feed, but without corroborating evidence, these remain speculative. The absence of real-time news coverage itself is noteworthy and typical for stocks at this price and market-cap level.

LNZA

LanzaTech Global, Inc.Industrials

$8.03−$1.70

-17.5%

NASDAQ · Mkt cap $82 M

LNZA fell 17.47% on May 18, 2026, but no news headlines were published in the last 48 hours, so the specific catalyst remains unknown and may involve a delayed announcement, technical shift, or market-wide sector pressure.

No recent news headlines are available to explain the substantial single-day decline. LanzaTech is a carbon capture and transformation technology company, and stocks in this sector can be volatile due to sensitivity to energy prices, policy changes around carbon credits or climate regulation, and investor sentiment toward green technology funding. The sharp 17.47% drop without visible news could reflect a delayed earnings release, guidance revision, analyst downgrade, regulatory development, partnership announcement, or broader market repositioning in clean energy stocks. Without headlines, any specific explanation would be speculative, though companies in capital-intensive technology sectors commonly see large single-day moves on quarterly results, funding announcements, or shifts in subsidy expectations.

BEEM

Beam GlobalTechnology

$1.43−$0.30

-17.3%

NASDAQ · Mkt cap $27 M

Beam Global dropped 17.34% despite reporting record European orders and a promising patent. The disconnect suggests a broader market or company-specific concern not captured in the available headlines, such as guidance cuts, margin pressure, or cash burn disclosures in the full earnings report.

The two headlines provided are decidedly positive: Beam Europe announced record $1.7 million in smart city infrastructure orders in a single week across five European countries, and the company received recognition for a patent with cited upside potential of 52.97%. Yet the stock fell sharply, ranking as the 50th biggest loser of the day. This significant disconnect between headline positivity and price action suggests the market reacted to information not fully captured in these snippets. The most likely explanations are that the full Q1 2026 earnings transcript contained negative guidance, disappointing profitability metrics, higher cash burn than expected, or concerns about order-to-revenue conversion and execution risk. Alternatively, the market may have repriced the entire renewable energy or EV charging sector downward on macro headwinds unrelated to Beam Global's fundamentals.